Matrix metalloproteinases: Biologic activity and clinical implications

Journal of Clinical Oncology

Volumn 18, Issue 5, 2000, Pages 1135-1149

  Nelson, Amy R ^a   Fingleton, Barbara ^a   Rothenberg, Mace L ^a   Matrisian, Lynn M ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; TANOMASTAT;

ARTICLE; CANCER; CANCER INVASION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0033999308     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.5.1135     Document Type: Article

References (154)

1. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87:159-170, 1996
2. Fidler IJ: Molecular biology of cancer: Invasion and metastasis, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 135-152
3. Yurchenco PD, Schittny JC: Molecular architecture of basement membranes. FASEB J 4:1577-1590, 1990
4. Barsky SH, Siegal GP, Jannotta F, et al: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 49:140-147, 1983
5. Liotta LA, Tryggvason K, Garbisa S, et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67-68, 1980
6. Woessner JF Jr: The matrix metalloproteinase family, in Parks WC, Mecham RP (eds): Matrix Metalloproteinases. San Diego, CA, Academic Press, 1998, pp 1-14
7. Sato H, Seiki M: Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem 119:209-215, 1996
8. Kinoh H, Sato H, Tsunezuka Y, et al: MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 109:953-959, 1996
9. Strongin AY, Collier IE, Bannikov G, et al: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270: 5331-5338, 1995
10. Knäuper V, Will H, Lopez-Otin C, et al: Cellular mechanisms for human procollagenase-3 (MMP-13) activation: Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 271:17124-17131, 1996
11. Fini ME, Cook JR, Mohan R, et al : Regulation of MMP gene expression, in Parks WC, Mecham RP (eds): Matrix Metalloproteinases. San Diego, CA, Academic Press, 1998, pp 299-356
12. Knäuper V, Murphy G: Membrane-type matrix metalloproteinases and cell surface-associated activation cascades for matrix metalloproteinases, in Parks WC, Mecham RP (eds): Matrix Metalloproteinases. San Diego, CA, Academic Press, 1998, pp 199-218
13. Docherty AJ, Lyons A, Smith BJ, et al: Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318:66-69, 1985
14. Wolfsberg TG, Primakoff P, Myles DG, et al: ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: Multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 131:275-278, 1995
15. Wolfsberg TG, Bazan JF, Blobel CP, et al: The precursor region of a protein active in sperm-egg fusion contains a metalloprotease and a disintegrin domain: Structural, functional, and evolutionary implications. Proc Natl Acad Sci U S A 90:10783-10787, 1993
16. Nath D, Slocombe PM, Stephens PE, et al: Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci 112:579-587, 1999
17. Bronson RA, Fusi FM, Calzi F, et al: Evidence that a functional fertilin-like ADAM plays a role in human sperm-oolemmal interactions. Mol Hum Reprod 5:433-440, 1999
18. Amour A, Slocombe PM, Webster A, et al: TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435:39-44, 1998
19. Matrisian LM, Glaichenhaus N, Gesnel MC, et al: Epidermal growth factor and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts. EMBO J 4:1435-1440, 1985
20. Goldberg G, Wilhelm SM, Kronberger A, et al: Human fibroblast collagenase: Complete primary structure and homology to an oncogene transformation-induced rat protein. J Biol Chem 261:6600-6605, 1986
21. Nabeshima K, Lane WS, Biswas C: Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor. Arch Biochem Biophys 285:90-96, 1991
22. Basset P, Bellocq JP, Wolf C, et al: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699-704, 1990
23. Monsky WL, Kelly T, Lin C-Y, et al: Binding and localization of (M)r 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res 53:3159-3164, 1993
24. Remacle AG, Noel A, Duggan C, et al: Assay of matrix metalloproteinases types 1,2,3 and 9 in breast cancer. Br J Cancer 77:926-931, 1998
25. Davies B, Miles DW, Happerfield LC, et al: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67:1126-1131, 1993
26. Polette M, Gilbert N, Stas I, et al: Gelatinase A expression and localization in human breast cancers: An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch Int J Pathol 424:641-645, 1994
27. Rha SY, Yang WI, Kim JH, et al: Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 5:875-879, 1998
28. Kurizaki T, Toi M, Tominaga T: Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Reports 5:673-677, 1998
29. Heppner KJ, Matrisian LM, Jensen RA, et al: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149:273-282, 1996
30. Ahmed A, Hanby A, Dublin E, et al: Stromelysin-3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol 152:721-728, 1998
31. Nielsen BS, Sehested M, Kjeldsen L, et al: Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 77:345-355, 1997
32. Newell KJ, Witty JP, Rodgers WH, et al: Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 10:199-206, 1994
33. Wolf C, Rouyer N, Lutz Y, et al: Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci U S A 90:1843-1847, 1993
34. Chenard MP, O'Siorain L, Shering S, et al: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 69:448-451, 1996
35. Linder C, Engel G, Auer G, et al: Distribution of stromelysin-3 mRNA transcripts and microvessels in human breast carcinomas. Breast Cancer Res Treat 42:207-213, 1997
36. Kawami H, Yoshida K, Ohsaki A, et al: Stromelysin-3 mRNA expression and malignancy: Comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors. Anticancer Res 13:2319-2324, 1993
37. Freije JMP, Díez-Itza I, Balbín M, et al: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269:16766-16773, 1994
38. Ueno H, Nakamura H, Inoue M. et al: Expression and tissue localization of membrane-types 1,2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 57:2055-2060, 1997
39. Polette M, Nawrocki B, Gilles C, et al: MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch 428:29-35, 1996
40. Okada A, Bellocq J-P, Chenard M-P, et al: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast and head and neck carcinomas. Proc Natl Acad Sci U S A 92:2730-2734, 1995
41. Murray GI, Duncan ME, O'Neil P, et al: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185:256-261, 1998
42. Grigioni WF, D'Errico A, Fiorentino M, et al: Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties. Diagn Mol Pathol 3:163-169, 1994
43. Pyke C, Ralfkiær E, Tryggvason K, et al: Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142:359-365, 1993
44. Poulsom R, Pignatelli M, Stetler-Stevenson WG, et al: Stromal expression of 72 kda Type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141:389-396, 1992
45. Gallegos NC, Smales C, Savage FJ, et al: The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol 4:111-119, 1995
46. McDonnell S, Navre M, Coffey RJ, et al: Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 4:527-533, 1991
47. Zeng ZS, Guillem JG: Colocalisation of matrix metalloproteinase-9 mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 74:1161-1167, 1996
48. Takeha S, Fujiyama Y, Bamba T, et al: Stromal expression of mmp-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: A novel approach from immune/inflammatory aspect. Jap J Cancer Res 88:72-81, 1997
49. Kossakowska AE, Huchcroft SA, Urbanski SJ, et al: Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 73:1401-1408, 1996
50. Thewes M, Pohlmann G, Atkinson M, et al: Stromelysin-3 (st-3) mrna expression in colorectal carcinomas: Localization and clinicopathologic correlations. Diagn Mol Pathol 5:284-290, 1996
51. Brown PD, Bloxidge RE, Stuart NSA, et al: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85:574-578, 1993
52. Nakagawa H, Yagihashi S: Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung. Jap J Cancer Res 85:934-938, 1994
53. Kodate M, Kasai T, Hashimoto H, et al: Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 47:461-469, 1997
54. Nawrocki B, Polette M, Marchand V, et al: Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses. Int J Cancer 72:556-564, 1997
55. Soini Y, Pääkkö P, Autio-Harmainen H: Genes of laminin B1 chain, alpha-1 (IV) chain of type IV collagen, and 72-kd type IV collagenase are mainly expressed by the stromal cells of lung carcinomas. Am J Pathol 142:1622-1630, 1993
56. Bolon I, Devouassoux M, Robert C, et al: Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol 150:1619-1629, 1997
57. Tolnay E, Wiethege T, Kuhnen C, et al: Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer. J Cancer Res Clin Oncol 123:652-658, 1997
58. Canete-Soler R, Litzky L, Lubensky I, et al: Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am J Pathol 144:518-527, 1994
59. Anderson IC, Sugarbaker DJ, Ganju RK, et al: Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblast. Cancer Res 55:4120-4126, 1995
60. Tokuraku M, Sato H, Murakami S, et al: Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the express ion of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 64:355-359, 1995
61. Jung K, Nowak L, Lein M, et al: Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1 tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 74:220-223, 1997
62. Wood M, Fudge K, Mohler JL, et al: In situ hybridization studies of metalloproteinases 2 and 9 and timp-1 and timp-2 expression in human prostate cancer. Clin Exp Metastasis 15:246-258, 1997
63. Pajouh MS, Nagle RB, Breathnach R, et al: Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117:144-150, 1991
64. Stearns ME, Stearns M: Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 8:63-67, 1996
65. Stearns ME, Wang M: Type IV collagenase (Mr 72,000) expression in human prostate: Benign and malignant tissue. Cancer Res 53:878-883, 1993
66. Montironi R, Lucarini G, Castaldini C, et al: Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer Res 16:2057-2622, 1996
67. Knox JD, Wolf C, McDaniel K, et al: Matrilysin expression in human prostate carcinoma. Mol Carcinog 15:57-63, 1996
68. Hashimoto K, Kihira Y, Matuo Y, et al: Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 160:1872-1876, 1998
69. Hamdy FC, Fadlon EJ, Cottam D, et al: Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 69:177-182, 1994
70. Koshiba T, Hosotani R, Wada M, et al: Detection of matrix metalloproteinase activity in human pancreatic cancer. Surg Today 27:302-304, 1997
71. Bramhall SR, Stamp GWH, Dunn J, et al: Expression of collagenase (mmp2), stromelysin (mmp3) and tissue inhibitor of the metalloproteinases (timp1) in pancreatic and ampullary disease. Br J Cancer 73:972-978, 1996
72. Gress TM, Mueller-Pillasch F, Lerch MM, et al: Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 62:407-413, 1995
73. Imamura T, Ohshio G, Mise M, et al: Expression of membrane-type matrix metalloproteinase-1 in human pancreatic adenocarcinomas. J Cancer Res Clin Oncol 124:65-72, 1998
74. Young TN, Rodriguez GC, Rinehart AR, et al: Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2. Gynecol Oncol 62:89-99, 1996
75. Naylor MS, Stamp GW, Davies BD, et al: Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer 58:50-56, 1994
76. Fishman DA, Bafetti LM, Stack MS: Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 16:150-159, 1996
77. McDonnell S, Matrisian LM: Stromelysin in tumor progression and invasion. Cancer Metastasis Rev 9:305-319, 1991
78. MacDougall JR, Bani MR, Lin Y, et al: The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cell. Cancer Res 55:4174-4181, 1995
79. Vaisanen A, Tuominen H, Kallioinen M, et al: Matrix metalloproteinase-2 (72 kd type iv collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 180:283-289, 1996
80. Brown PD, Bloxidge RE, Anderson E, et al: Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 11:183-189, 1993
81. Tetu B, Brisson J, Lapointe H, et al: Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. Hum Pathol 29:979-985, 1998
82. Gohji K, Fujimoto N, Hara I, et al: Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 79:96-101, 1998
83. Baker T, Tickle S, Wasan H, et al: Serum metalloproteinases and their inhibitors: Markers for malignant potential. Br J Cancer 70:506-512, 1994
84. Murray GI, Duncan ME, Oneil P, et al: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2:461-462, 1996
85. Ichikawa Y, Ishikawa T, Momiyama N, et al: Detection of regional lymph node metastases in colon cancer by using RT-PCR for matrix metalloproteinase-7, matrilysin. Clin Exp Metastasis 16:3-8, 1998
86. Yamamoto H, Adachi Y, Itoh F, et al: Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 59:3313-3316, 1999
87. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270, 1997
88. Schultz RM, Silberman S, Persky B, et al: Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 48:5539-5545, 1988
89. Kawamata H, Kameyama S, Kawai K, et al: Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer 63:568-575, 1995
90. Bernhard EJ, Gruber SB, Muschel RJ: Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 91:4293-4297, 1994
91. Tsunezuka Y, Kinoh H, Takino T, et al: Expression of memv-brane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 56:5678-5683, 1996
92. Hasegawa S, Koshikawa N, Momiyama N, et al: Matrilysin-specific oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 76:812-816, 1998
93. Khokha R, Zimmer MJ, Wilson SM, et al: Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis 10:365-370, 1992
94. Koop S, Khokha R, Schmidt EE, et al: Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 54:4791-4797, 1994
95. Koop S, Schmidt EE, MacDonald IC, et al: Independence of metastatic ability and extravasation: Metastatic ras-transformed and control fibroblasts extravasate equally well. Proc Natl Acad Sci USA 93:11080-11084, 1996
96. Powell WC, Knox JD, Navre M, et al: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53:417-422, 1993
97. Kim J, Yu W, Kovalski K, et al: Requirement for specific proteases in cancer cell intravasation as revealed by a novel semi-quantitative PCR-based assay. Cell 94:353-362, 1998
98. Itoh T, Tanioka M, Yoshida H, et al: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58:1048-1051, 1998
99. Vu TH, Shipley JM, Bergers G, et al: MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411-422, 1998
100. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 103:1237-1241, 1999
101. Witty JP, McDonnell S, Newell K, et al: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 54:4805-4812, 1994
102. Noel AC, Lefebvre O, Maquoi E, et al: Stromelysin-3 expression promotes tumor take in nude mice. J Clin Invest 97:1924-1930, 1996
103. Masson R, Lefebvre O, Noel A, et al: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 140:1535-1541, 1998
104. D'Armiento J, DiColandrea T, Dalal SS, et al: Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol 15:5732-5739, 1995
105. Wilson CL, Heppner KJ, Labosky PA, et al: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 94:1402-1407, 1997
106. Goss KJ, Brown PD, Matrisian LM: Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78:629-635, 1998
107. Davies B, Brown PD, East N, et al: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087-2091, 1993
108. Wang X, Fu X, Brown PD, et al: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726-4728, 1994
109. Zervos EE, Norman JG, Gower WR, et al: Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 69:367-371, 1997
110. Sledge GWJ, Qulali M, Goulet R, et al: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87:1546-1550, 1995
111. Chirivi RGS, Garofalo A, Crimmin MJ, et al: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460-464, 1994
112. Eccles SA, Box GM, Court WJ, et al: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56:2815-2822, 1996
113. Price A, Shi Q, Morris D, et al: Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 5:845-854, 1999
114. Johnston MR, Mullen JBM, Pagura M, et al: AG3340, a novel matrix metalloproteinase inhibitor, decreases growth and metastasis of orthotopic human lung cancer in a nude rat preclinical model system. Proc Am Assoc Cancer Res 39: 302, 1998 (abstr)
115. Nozaki S, Sissons S, Casazza AM, et al: Inhibition of human breast cancer regrowth and pulmonary metastasis by BAY 12-9566 in athymic mice. Proc Am Assoc Cancer Res 39: 301, 1998 (abstr)
116. Flynn C, Bull C, Eberwein D, et al: Anti-metastatic activity of BAY 12-9566 in a human colon carcinoma HCT116 orthotopic model. Proc Am Assoc Cancer Res 39: 301, 1998 (abstr)
117. Knox JD, Bretton L, Lynch T, et al: Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. Prostate 35:248-254, 1998
118. Van den Oord JJ, Paemen L, Opdenakker G, et al: Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 151:665-670, 1997
119. Shalinsky DR, Zou H, McDermott CD, et al: AG3340, a selective MMP inhibitor, has broad antiangiogenic activity across oncology and ophthalmology models in vivo. Proc Am Assoc Cancer Res 40:66, 1999 (abstr)
120. Anderson IC, Shipp MA, Docherty AJ, et al: Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 56:715-718, 1996
121. Neri A, Goggin B, Kolis S, et al: Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice. Proc Am Assoc Cancer Res 39:302, 1998 (abstr)
122. Giavazzi R, Garofalo A, Ferri C, et al: Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 4:985-992, 1998
123. Beattie GJ, Smyth JF: Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 4:1899-1902, 1998
124. Parsons SL, Watson SA, Steele RJ: Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Cancer 23:526-531, 1997
125. Wojtowicz-Praga S, Torri J, Johnson M, et al: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 16:2150-2156, 1998
126. Bodurtha A, Eisenhauer E, Steward W, et al: Phase I-II study of marimastat (BB-2516) in patients with metastatic melanoma. Proc Am Soc Clin Oncol 16:493a, 1997 (abstr 1775)
127. Parsons SL, Watson SA, Griffin NR, et al: An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer. Ann Oncol 47:47, 1996 (abstr) (suppl 5)
128. Evans J, Bramhall S, Carmichael J, et al: A phase II study of marimastat (BB-2516) in advanced pancreatic cancer. Ann Oncol 7:51, 1996 (abstr) (suppl 5)
129. Rosemurgy A, Harris J, Langleben A, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 15:207, 1996 (abstr 470)
130. Poole C, Adams M, Barley V, et al: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor in patients with advanced ovarian cancer. Ann Oncol 7:68, 1996 (abstr) (suppl 5)
131. Boasberg P, Harbaugh B, Eisenberger M, et al: Marimastat in patients with hormone refractory prostate cancer: A dose-finding study. Proc Am Soc Clin Oncol 16:316a, 1997 (abstr 1126)
132. Boasberg P, Harbaugh B, Roth B, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 15:258, 1996 (abstr 671)
133. Hande K, Wilding G, Ripple G, et al: A phase I study of AG334, a matrix metalloprotease inhibitor, in patients having advanced cancer. Ann Oncol 9:74, 1998 (abstr) (suppl 2)
134. Erlichman C, Adjei A, Alberts S, et al: Phase I study of BAY 12-9566: A matrix metalloproteinase inhibitor. Proc Am Soc Clin Oncol 17:217a, 1998 (abstr 837)
135. Goel R, Hirte H, Shah A, et al: Phase I study of the metalloproteinase inhibitor Bayer 12-9566. Proc Am Soc Clin Oncol 17:217a, 1998 (abstr 840)
136. Grochow L, O'Reilly S, Humphrey R, et al: Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor, BAY 12-9566. Proc Am Soc Clin Oncol 17:213a, 1998 (abstr 822)
137. Hirte H, Goel R, Bennett K, et al: Phase I study of the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced cancer. Ann Oncol 9:75, 1998 (abstr) (suppl 2)
138. Levitt NC, Eskens F, Propper DJ, et al: A phase I pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor. Proc Am Soc Clin Oncol 17:213a, 1998 (abstr 823)
139. Macaulay VM, O'Byrne KJ, Saunders MP, et al: Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5:513-520, 1999
140. Primrose J, Bleiberg H, Daniel F, et al: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer. Ann Oncol 7:35, 1996 (abstr) (suppl 5)
141. Zaknoen S, Wolff R, Cox J, et al: Marimastat in advanced progressive colorectal cancer: A dose-finding study. Proc Am Soc Clin Oncol 16:273a, 1997 (abstr 968)
142. Malfetano J, Teng N, Barter J, et al: Marimastat in patients with advanced cancer of the ovary: A dose-finding study. Proc Am Soc Clin Oncol 16:373a, 1997 (abstr 1331)
143. Nemunaitis J, Poole C, Primrose J, et al: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4:1101-1109, 1998
144. Rosemurgy A, Buckels J, Charnley R: A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 18:261a, 1999 (abstr 1005)
145. British Biotech plc: Results of marimastat study 128: Pancreatic cancer monotherapy trial. Release date, 2/5/99. Http:www.britbio-.co.uk/news/128.txt
146. British Biotech plc: Results of marimastat study 145 in gastric cancer. Release date, 8/24/99. Http:www.britbio.co.uk/news/ 990824.txt
147. Adams M, Thomas H: A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer. Proc Am Soc Clin Oncol 17:217a, 1998 (abstr 838)
148. Carmichael J, Ledermann JA, Woll PJ, et al: Phase 1B study of concurrent administration of marimastat and gemcitabine in nonresectable pancreatic cancer. Proc Am Soc Clin Oncol 17:232a, 1998 (abstr 888)
149. Gradishar W, Sparano J, Cobleigh M, et al: A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:144a, 1998 (abstr 548)
150. Wilding G, Small E, Ripple G, et al: Phase I study of AG3340, a matrix metalloproteinase inhibitor, in combination with mitoxantrone/prednisone in patients having advanced prostate cancer. Ann Oncol 9:74, 1998 (abstr) (suppl 2)
151. Chouinard E, Goel R, Hirte HW, et al: A phase I interaction study between BAY 12-9566 and doxorubicin in cancer patients. Proc Am Assoc Cancer Res 40:84, 1999 (abstr)
152. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195, 1993
153. Shridhar R, Sloane BF, Keppler D: Inhibitors of papain-like cysteine peptidases in cancer, in von der Helm K, Cheronis J, Korant B (eds): Proteases as Targets for Therapy. New York, NY, Springer-Verlag, (in press)
154. Ikeda T, Murakami K, Hayakawa Y, et al: Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor. Anticancer Res 18:4259-4265, 1998